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Progress in isolating stem cells from tissues, or generating them
from adult cells by nuclear transfer, encourages attempts to use
stem cells from affected individuals for gene correction and autol-
ogous therapy. Current viral vectors are efficient at introducing
transgenic sequences but result in random integrations. Gene
targeting, in contrast, can directly correct an affected gene, or
incorporate corrective sequences into a site free from undesirable
side effects, but efficiency is low. Most current targeting proce-
dures, consequently, use positive-negative selection with drugs,
often requiring >10 days. This drug selection causes problems with
stem cells that differentiate in this time or require feeder cells,
because the feeders must be drug resistant and so are not elimi-
nated by the selection. To overcome these problems, we have
developed a procedure for isolating gene-corrected stem cells free
from feeder cells after 3–5 days culture without drugs. The method
is still positive-negative, but the positive and negative drug-
resistance genes are replaced with differently colored fluorescence
genes. Gene-corrected cells are isolated by FACS. We tested the
method with mouse ES cells having a mutant hypoxanthine phos-
phoribosyltransferase (Hprt) gene and grown on feeder cells. After
5 days in culture, gene-corrected cells were obtained free from
feeder cells at a ‘‘purity’’ of >30%, enriched >2,000-fold and with
a recovery of 20%. Corrected cells were also isolated singly for
clonal expansion. Our FACS-based procedure should be applicable
at small or large scale to stem cells that can be cultured (with feeder
cells, if necessary) for >3 days.
electroporation  flow cytometry  fluorescent protein  gene targeting 
gene therapy
Hematopoietic stem cells (HSC) are among the longestknown and best studied stem cells (1). They are character-
ized by their ability to fully repopulate the bone marrow of
suitably prepared recipients and have been used therapeutically
in the form of bone marrow transplants for several decades. HSC
are, however, difficult to culture ex vivo without differentiating,
and normal HSC have been induced to increase to only about six
times the input number of HSC in vitro (2). The in vitro expansion
of HSC from experimental animals has been enhanced (up to
approximately forty times input) by the introduction of trans-
genes coding for MDR1 or HOXB4 (3, 4), but HSC cannot
currently be clonally expanded in vitro. Their ability to self-
replicate extensively in vivo is, however, undoubted because a
single HSC is sufficient to repopulate the bone marrow of a
recipient, which can then be used to repopulate the bone
marrows of secondary recipients (5, 6).
The history of bone marrow transplantations clearly empha-
sizes that problems are likely to arise when there are histocom-
patibility differences between donors and recipients. Thus, the
first successful bone marrow transplant was with an identical
twin (genetically an autologous transplant) (7). Only the subse-
quent elucidation of histocompatibility antigens allowed success
with allogeneic transplants (8). But, even now, the need for
pretransplant myeloablation with cytotoxic drugs andor irra-
diation and the need for posttransplant immune suppression
limits the use of bone marrow transplantation to life-threatening
conditions. Despite these limitations, bone marrow or cord
blood transplantation is the only curative treatment for many
malignancies of the hematopoietic system, for severe aplastic
anemia, and for severe combined immunodeficiency. Beta zero
thalassemia is the only common genetic disease for which bone
marrow or cord blood transplantation is generally accepted,
although it is a possibility for sickle cell anemia (9). In both these
conditions, the availability of an HLA-compatible donor is an
important consideration.
Because securing histocompatible donors is often difficult or
impossible, and because of the high risk of graft-versus-host
disease, considerable efforts have been made to develop ways of
correcting the genetic defect in HSC from affected individuals
and of using the corrected cells for autologous transplantation.
Transfer into the HSC of a functional copy of the affected gene,
typically with a viral vector, has received the most attention. The
procedure is highly effective, with transfection frequencies ap-
proaching 20% (10, 11). Unfortunately, there is no control over
the sites where virally transduced sequences incorporate into the
genome, and this lack has led to the occurrence of leukemia in
some patients with adenosine deaminase deficiency in whom the
original defect had been corrected by retroviral gene therapy
(12). Homologous recombination (gene targeting) is an alter-
native method of correcting genetic defects (13, 14). The af-
fected gene can be corrected directly, or a functional copy of the
gene can be introduced into a locus known to be free from
significant side effects [such as the hypoxanthine phosphoribo-
syltransferase (Hprt) locus]. The low efficiency of gene targeting
(of the order of 1 corrected cell in 105 treated cells, when tested
in ES cells) and the low frequency of stem cells in total bone
marrow (of the order of 1 stem cell per 104 to 105 nucleated cells)
has currently precluded its successful application to HSC.
Gene correction by homologous recombination has, never-
theless, been demonstrated to occur in mouse hematopoietic
progenitor cells (HPCs), which are more common in bone
marrow (of the order of 2 HPC per 103 nucleated cells), and the
frequency of recombination was indistinguishable from that
obtained with ES cells (15). The gene defect corrected in the
HPC experiments was a mutation in the Hprt gene that would
cause Lesch–Nyhan disease in human males. Corrected cells
were identified by their ability to form colonies in a selective
medium that kills uncorrected cells. However, because this type
of direct selection of targeted cells is possible for only a very few
genes, indirect strategies for gene targeting have been devel-
oped. The positive-negative strategy devised by Mansour et al.
(16) is most commonly used; it identifies targeted cells by their
ability to form colonies resistant to two drugs. Its application in
stem cells is limited to those that remain undifferentiated for the
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time required for uncorrected (drug-sensitive) cells to be killed
and for corrected (drug-resistant) cells to form colonies (typi-
cally 10 days). Some stem cells, including HSC, are difficult to
maintain undifferentiated in culture for this length of time, some
do not form colonies, and some survive ex vivo only in the
presence of accessory cells, which must be resistant to the
selective drugs and so are not eliminated by them.
To overcome these limitations and restrictions, we have
developed a FACS-based gene-targeting strategy that can be
applied to any stem cells that can be cultured (with feeder cells,
if necessary) for 3 days without differentiating. The stem cells
do not have to be clonable, although the procedure can isolate
cells singly for use with stem cells that can be clonally expanded.
We have tested the procedure by correcting a mutation in the
Hprt gene in ES cells. Gene-corrected cells were obtained in bulk
with a recovery of 20%, enrichment 2,000, and at a ‘‘purity’’
of 30%.
Materials and Methods
Gene-Correcting Vectors. Two gene-correcting vectors were de-
rived from an Hprt-targeting vector previously described (17). A
green-positive, cyan-negative gene-correcting vector (Fig. 1A
Middle) was made by inserting sequences coding for an EGFP
(BD Clontech) between a BstBI and a BspEI site in the
Hprt-vector, and inserting sequences coding for an enhanced
cyan fluorescence protein (ECFP; BD Clontech) into the SalI
site of the vector. A cyan-positive, green-negative gene-
correcting vector (see Fig. 3C) was made by inserting the ECFP
sequences between a BstBI and an AvrII site in the Hprt-
targeting vector, and inserting sequences coding for a humanized
Renilla GFP with a nuclear localizing sequence (hrGFP; Strat-
agene) into the SalI site. All f luorescence genes were driven by
a human -actin promoter together with its first intron (1.3 kb)
on a 1,311-bp AvrIIAluI fragment from a 4.3-kb sequence that
spans the promoter (18, 19) (accession no. AY582799).
Fluorescence-Activated Cell Sorting. Flow cytometry and sorting
were with a MoFlo cell sorter (DakoCytomation, Fort Collins,
CO). An argon-ion laser tuned to 458 nm (Coherent Innova-90)
with output set to 150 mW was used to excite GFP and cyan
fluorescent protein (CFP) (20). The CFP fluorescence was
separated from the GFP fluorescence with a 500-nm short-pass
dichroic mirror and collected with a 48530-nm band-pass (BP)
filter (Chroma Technology, Rockingham, VT). The GFP fluo-
rescence was collected with a 510AF23-nm BP filter (Omega
Optical, Brattleboro, VT). Red fluorescence used for autofluo-
rescence detection was separated with a 560-nm long-pass (LP)
dichroic mirror (Chroma Technology) and collected with a
575-nm alpha long-pass (ALP) filter (Omega Optical). When
sorting for GFP fluorescence only (Fig. 2), an argon-ion laser
tuned to 488 nm was used. Sorting was conducted at room
temperature (25°C).
Isolating Gene-Corrected Stem Cells. The mouse ES cells used in
our experiments were a subclone (BK4) of E14TG2a, a cell line
derived from 129Ola mice with a deletion in the Hprt gene (21).
The ES cells were grown and maintained on murine embryonic
fibroblasts in DMEM supplemented with 15% heat-inactivated
FBS, 10 M 2-mercaptoethanol, and 2 mM L-glutamine. Elec-
troporation was with 2  107 ES cells in the presence of 10 g
of the targeting DNA in a cuvette having a gap size of 4 mm and
an area of 160 mm2 with a 1-s discharge from a 250-F capacitor
charged to 300 V. The ES cells were maintained for 1–7 days,
with passages but without drug selection, on feeder layers of
irradiated murine embryonic fibroblasts. Cells were then dis-
persed with trypsin and sorted by differences in their forward
scatter (FSC), side scatter (SSC), and pulse width and by their
f luorescence after excitation with a 458-nm laser. Cells with
Fig. 1. Gene correction by homologous recombination with vectors
containing fluorescent protein genes. (A) A green-positive, cyan-negative
targeting vector for correcting a gene mutation by homologous recombi-
nation with a defective Hprt gene as an example. (Top) The structure of the
target gene, which has a deletion of 55 kb that removed the promoter
and exons 1 and 2, but left exons 3 through 9. (Middle) The gene-correcting
vector, which includes a GFP gene and the missing Hprt promoter P and
exons 1 and 2 all flanked by the homologous sequences that control the
recombination. A CFP gene, located outside the homologous regions, is
also part of the targeting vector. (Bottom) The corrected gene with the GFP
gene used for positive selection now adjacent to it. The CFP gene used for
negative selection is excluded by the homologous recombination. The
open boxes and line indicate the correcting DNA. The heavy horizontal
lines and filled boxes represent endogenous sequences and exons in the
target gene and homologous sequences in the correcting vector. The heavy
dashed line indicates bacterial sequences. (B) Mutant stem cells are elec-
troporated with correcting DNA and maintained on feeders for 1–7 days
with passages but without drug selection. Cells are dispersed with trypsin
and sorted by differences in their forward light scatter (FSC), side scatter
(SSC), and pulse width and by their fluorescence after excitation with a
458-nm laser. Cells with green or green plus cyan, or cyan fluorescence are
collected in bulk, or singly into the wells of a 384-well plates. Doublets, cells
with no fluorescence, or cells fluorescing red are discarded. Colonies
derived from sorted cells are counted before and after HAT selection.
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‘‘green’’ or ‘‘green plus cyan’’ or ‘‘cyan’’ f luorescence were
collected in bulk, or singly into the wells of 384-well plates in
which feeder cells were already present. Doublets, cells with no
fluorescence, or cells f luorescing ‘‘red’’ were discarded. To
assess the frequency of gene correction, the sorted cells were
plated for colony formation, and the numbers of colonies were
counted with and without HAT selection (16 gml hypoxan-
thine, 0.175 gml aminopterin, and 4.8 gml thymidine in the
ES cell medium described above) for 7 days.
Assessing Transient Gene Expression. To assess the frequency and
time course of transient expression (Fig. 2) of the electroporated
gene-targeting construct, we used the green-positive, cyan-
negative construct and the same general procedures as in a
full-scale sorting experiment except that we sorted only by green
fluorescence. Green-positive cells were collected in bulk at days
1–6 after electroporation. The percentage of cells in which gene
correction had been achieved was determined by plating the
collected cells for colony formation and by counting the numbers
of resulting colonies with and without HAT selection. The
colonies were also scored for fluorescence.
Results and Discussion
Gene-Targeting with Two Fluorescence Genes. To develop our
FACS-based procedure, we used male-derived mouse ES cells
having a deletion mutation in the X-linked Hprt gene, which
enables easy detection of gene correction by testing for resistance
to HAT. Our procedure retains the positive-negative strategy
first described by Capecchi and his collaborators (16), but the
positively selectable drug resistance gene (typically a neomycin
phosphotransferase gene) is replaced with a gene coding for a
GFP. This GFP gene is inserted into the target locus when
homologous recombination occurs. Cells having the desired
gene correction therefore fluoresce green. The conventional
negatively selectable gene (typically a viral thymidine kinase
gene) is replaced with a CFP gene located outside the sequences
involved in the homologous recombination. This CFP gene is
eliminated when homologous recombination occurs. Corrected
cells therefore have no cyan fluorescence. Cells incorporating
the CFP gene nonhomologously into their genomes fluoresce
cyan. Cells in which gene correction has been achieved are
consequently green-positive, cyan-negative (Fig. 1 A).
The overall procedure (summarized in Fig. 1B) uses electro-
poration to introduce a gene-correcting vector into the mutant
stem cells. After the electroporation, the treated cells are
cultured in nonselective medium for 1–7 days in the presence of
feeder cells. The cultured cells are then dispersed with trypsin
and sorted by their green andor cyan fluorescence under a
458-nm excitation, with prior gating to discard debris, feeder
cells, doublets, and autofluorescing cells. Sorting for green-
positive, cyan-negative cells recovers corrected cells and elimi-
nates any feeder cells that escape the prior gating because the
feeder cells do not fluoresce green. Gene-corrected cells can be
isolated in bulk, or singly for clonal expansion. (Details of the
criteria for prior gating and for distinguishing green and cyan
fluorescing cells are in Fig. 4, which is published as supporting
information on the PNAS web site.)
Fates of Exogenous DNA. Gene-correcting DNA introduced into a
cell can result in at least three nonexclusive outcomes. (i) The
DNA may remain for a time in the cells and be transiently
expressed but never integrated into the genome. (ii) The DNA,
whole or in fragments, may be incorporated nonhomologously
into the genome. (iii) The DNA may recombine homologously
and correct the mutant gene. The relative frequency of these
outcomes varies with the DNA construct and the target locus,
but in general their frequencies are i  ii  iii. Our initial
experiments were therefore aimed primarily at determining the
time course and relative frequencies of these three outcomes.
For this purpose, we used the green-positive, cyan-negative
vector shown in Fig. 1 A, but sorted positively only for green
fluorescence together with prior gating to exclude feeder cells,
debris, and cell doublets. Fig. 2 shows that, after 1 day in culture,
1.89% of the trypsinized cells f luoresced green. This percentage
decreased progressively until, after 5 days, it stabilized at
0.05%.
To ascertain the types of events that had occurred in the
fluorescing cells collected on the different days, we plated the
sorted green-fluorescing cells onto feeder layers for culture with
or without HAT in the medium. The resulting colonies were then
scored for gene correction (HAT-resistant), or lack of correction
(HAT-sensitive) and examined visually for their f luorescence.
(Note that the HAT selection is used only as an assay for gene
correction; it is not a part of the gene-targeting process. It can
be replaced by other assays, such as PCR or Southern blotting.)
Fig. 2 shows that the vast majority (1.871.89  99%) of the
1.89% of input cells that fluoresced green at day 1 give rise to
nonfluorescing colonies when expanded (open bars in the fig-
ure), indicating that they expressed GFP only transiently (out-
come i). The percentage of green-fluorescing cells decreased
10-fold over days 2 through 4 as transient expression de-
creased, so that, by day 5, and stably thereafter, only 0.05% of
the input cells f luoresced green. Transient expression is unlikely
to persist for 5 days, yet we found that 20% of the green-
fluorescing cells collected at days 5 and 6 gave nonfluorescing
colonies. We interpret these colonies as representing a small
Fig. 2. The time course of events after culture for 1–6 days after electropo-
ration with the green-positive, cyan-negative vector diagramed in Fig. 1A. The
vertical axis shows the percentage of sorted cells fluorescing green. Open bars
indicate cells that produce nonfluorescing colonies when expanded. Gray bars
indicate cells that produce green-fluorescing HAT-sensitive colonies; these are
cells that have incorporated the GFP gene into their genomes nonhomolo-
gously. Black bars indicate cells that produce green-fluorescing HAT-resistant
colonies; these are the cells in which the mutant gene has been corrected by
homologous recombination. The numbers in the boxes show the percentages
of sorted cells falling into the three categories indicated by the shading of the
bars. The error bars show the standard errors of the results from four exper-
iments. Note that, although a green-positive, cyan-negative vector was used
in this experiment, sorting was only for green fluorescence. Note also that the
vertical axis of the figure is interrupted and has two scales.











background percentage (0.01%) of unmodified cells mis-sorted
as green-fluorescing during the initial FACS. This interpretation
is supported by the results of Southern blotting DNA isolated
from several of the nonfluorescing colonies; the DNA contained
no detectable vector sequences (data not shown).
The percentage of sorted cells that gave rise to green-
fluorescing colonies increased as integration of the GFP gene
into the genome increased (gray plus black bars in Fig. 2) from
0.017% at day 1 to 0.037% at day 4 and thereafter. At day 1, all
of the green-fluorescing colonies were HAT-sensitive (gray
bars), showing that they are nonhomologous integrants (out-
come ii). At day 4, 5% of the green-fluorescing colonies (derived
from 0.0025% of the input cells) were HAT-resistant (solid black
bars in Fig. 2), showing that the mutation had been corrected in
these cells (outcome iii). By day 5, when the percentage of
transiently expressing cells had decreased to an insignificant
level and the proportion of cells in the three categories had
stabilized, we find that 1 in 20 (5%) of the sorted green-
fluorescing cells are gene-corrected; 75% are nonhomologous
GFP integrants; and 20% are unmodified cells.
Isolation of Gene-Corrected Stem Cells by Multichannel-FACS Sorting.
A 4-fold improvement in the efficiency of discarding noncor-
rected cells with the vector shown in Fig. 1 A was achieved by
using red and cyan fluorescence in addition to green together
with the prior gating to exclude feeder cells, debris and cell
doublets (Fig. 3A). The addition of red fluorescence enables the
detection and therefore exclusion of a quite minor but nonethe-
less significant proportion of feeder and stem cells with back-
ground red and green autofluorescence. These cells give a signal
that encroaches on the green channel even in the absence of any
vector DNA; they can be eliminated by excluding cells that
fluoresce within the dashed polygon in Fig. 3B. (Square bracket
no. 1 in the figure indicates autofluorescing feeder cells; square
bracket no. 2 indicates autofluorescing stem cells.) The addition
of cyan fluorescence allows exclusion of cells that have nonho-
mologously incorporated cyan-coding sequences into their ge-
nomes, alone or accompanied with green-coding sequences. The
net result of using three fluorescent channels is that 1 in 5 (20%)
of the collected cells are now gene-corrected instead of 1 in 20
when using green only.
Table 1 summarizes quantitative data obtained from several
gene-correcting experiments with the green-positive, cyan-
negative vector shown in Fig. 3 A and B Lower. When no sorting
is used, 0.01% (0.0079  0.0008%) of the electroporated cells
are HAT-resistant (HATR) after 7 days in culture. When the
cells are sorted positively for green fluorescence, 5% (4.9 
0.8%) are HATR. Sorting positively for green fluorescence and
negatively for cyan and red fluorescence increases this to 20%
(19  2%) (1 in 5). Recovery after sorting is 20% (21  3%),
as judged by the number of HATR cells in the sorted populations
(61 or 66) compared with the number in the unsorted population
(316) after 7 days. Enrichment [(% of gene-corrected cells after
sorting)  (% of gene-corrected cells in the input)] is 2,000.
A further improvement was achieved by interchanging the
GFP and CFP genes in the correcting DNA vector, as illustrated
in Fig. 3C, with the result that now one in three of the sorted
cyan-fluorescing cells is gene corrected. This improvement is
largely because autofluorescence does not encroach on the cyan
channel. Accordingly, switching the positive fluorescence to
cyan and the negative to green eliminates the need to gate with
red fluorescence to remove autofluorescing cells. This cyan-
positive, green-negative vector is the one that we now use.
An obvious future improvement would flank the positive fluo-
rescent gene with lox P sites to allow for its removal in gene-
corrected stem cells. We also note that, if uncorrected stem cells are
acceptable in the sorted cell population, gene-corrected cells can be
isolated with no decrease in recovery by sorting after as few as 3
days in culture. This reduction in time is an important benefit with
stem cells (such as HSCs) that are difficult to maintain undiffer-
Fig. 3. Sorting criteria for collecting gene-corrected cells. (A) Green and cyan fluorescence used to collect gene-corrected cells 7 days after electroporation
introducing the green-positive, cyan-negative vector diagrammed at the bottom of the panel. The heavy polygon indicates the gating used for collecting
green-positive, cyan-negative cells (0.014% of the total input); one in five of these cells produces HATR colonies in which the mutant gene is corrected. Less than
1 in 1,000 of green-positive, cyan-positive cells (0.014% of input cells) and none of the green-negative, cyan-positive cells (0.009% of input cells) are HATR. Single
cells are shown in red. Yellow and blue indicate increasing numbers of cells. (B) Red and cyan fluorescence used to exclude cells with autofluorescence in
experiments with the green-positive, cyan-negative vector by rejecting cells within the dashed polygon (0.52% of input cells). These include minor fractions of
feeder cells and stem cells that autofluoresce, indicated by square brackets no. 1 and no. 2, respectively. (C) Green and cyan fluorescence used to collect
gene-corrected cells 7 days after electroporation introducing the cyan-positive, green-negative vector diagrammed at the bottom of the panel in which the CFP
and GFP genes of the earlier vector have been interchanged. The heavy polygon indicates the gating used to collect cyan-positive, green-negative cells (0.01%
of input cells); 1 in 3 of these cells produce HATR colonies in which the mutant gene has been corrected. Less than 1 in 1,000 of cyan-positive, green-positive cells
(0.022% of input cells) and none of the cyan-negative, green-positive cells (0.005% of input cells) are HATR. No significant autofluorescence encroaches on the
cyan channel, and so the red channel is not needed with this vector, which is the one currently used.
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entiated in culture. An important feature of our method is that it
allows the separation of individual cells into 384-well plates (as
illustrated in Fig. 1B) for use with stem cells that can be clonally
expanded. Correctly targeted clones can then be identified by PCR
or other means, and pooled or further expanded. This cloning
enables the recovery of stem cells free from any nonhomologous
integrants. If feeder cells are required during the clonal expansion,
they are easily removed by re-sorting.
General Considerations. Recent successes in isolating ES cells from
human blastocysts or generating them from adult cells by nuclear
transfer has catalyzed a tremendous surge in efforts to adapt
these versatile cells for treating human diseases. Two recent
experiments with partially differentiated ES cells illustrate some
of the possibilities. In one experiment, embryoid bodies gener-
ated in vitro from cloned human ES cells were able to provide
cells that acted as pacemakers after the embryoid bodies were
injected into the left ventricle of pig hearts in which the
atrioventricular bundle of His had been ablated (22). The
recipient animals were treated with immunosupressive drugs to
prevent immune rejection. In a different experiment, putative
endodermal precursors generated in vitro from cloned mouse ES
cells enabled the survival of factor IX-deficient hemophilic mice
after successful engraftment after injection into the liver paren-
chyma (23). Immune reactions were not observed despite a
complete MHC barrier, raising the interesting possibility that the
partially differentiated ES cells induced immune tolerance.
Mesenchymal stem cells (MSC) derived from adult bone marrow
may also have properties enabling them to avoid allogeneic
rejection (24). Nevertheless, the most certain way of avoiding
histocompatibility problems with stem cells or cells derived from
them is to use autologous grafts.
The fluorescence-based gene correction procedure we have
described here should be applicable on a small or large scale to
any type of stem cell for which culture conditions exist or can be
developed that permit survival of corrected cells for 3 days.
The procedure does not use drugs and can be used with stem cells
that require feeder or stromal cells for their maintenance during
culture or during ex vivo expansion, because they can be effi-
ciently removed by FACS. Our findings should encourage fur-
ther efforts to use gene targeting to correct or functionally
replace a mutant gene in stem cells for use in autologous gene
therapy.
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No. of cells 2  107 5951  177* 1655  48* 1660  84* 1066  82*
No. of colonies 4  106 1239  47 347  24 315  31 192  14
No. of HATR colonies 316  19 61  13 66  8 0 0
Percentage that are HATR 0.0079  0.0008 4.9  0.8 19  2 0.1 0
Percentage recovery — 19  3† 21  3† — —
Fold enrichment of
gene-corrected cells
— 620  56‡ 2433  401‡ — —
*Cell numbers are adjusted to an input of 2  107 cells per experiment and are presented as the mean of four experiments  standard
deviation.
†Percentage recovery  (no. of HATR colonies after sorting  100)  (no. of HATR colonies in the input cells).
‡Fold enrichment of gene-corrected cells  (% of HATR colonies after sorting)  (% of HATR colonies in the input cells).
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